Comparison of the adjuvanticity of two adjuvant formulations containing de-O-acylated lipooligosaccharide on Japanese encephalitis vaccine in mice

• Published in: Archives of pharmacal research Vol. 41; no. 2; pp. 219 - 228
• Main Authors: Ko, Ara, Wui, Seo Ri, Ryu, Ji In, Do, Hien Thi Thu, Lee, Yeon Jeong, Lim, Soo Jeong, Rhee, Inmoo, Jung, Dae Im, Park, Jin-ah, Choi, Jung-ah, Song, Man Ki, Lee, Na Gyong
• Format: Journal Article
• Language: English
• Published: Seoul Pharmaceutical Society of Korea 01.02.2018; 대한약학회
• Subjects: Acylation - immunology; adaptive immunity; adjuvants; Adjuvants, Immunologic - blood; agonists; alum; Animals; antibodies; antigens; Antigens, Bacterial - blood; Antigens, Bacterial - immunology; antiserum; blood serum; Drug Compounding; encephalitis; Female; immune response; immunoglobulin G; interferon-gamma; Japanese Encephalitis Vaccines - blood; Japanese Encephalitis Vaccines - immunology; lipooligosaccharides; Lipopolysaccharides - blood; Lipopolysaccharides - immunology; Medicine; Mice; Mice, Inbred BALB C; neutralization tests; Pharmacology/Toxicology; Pharmacy; Protein Binding - immunology; Research Article; Toll-like receptor 4; viral vaccines; 약학; Adjuvant formulation; De; Japanese encephalitis vaccine; acylated lipooligosaccharide; De-O-acylated lipooligosaccharide
• ISSN: 0253-6269; 1976-3786; 1976-3786
• DOI: 10.1007/s12272-017-0985-z

Adjuvants are essential vaccine components used to enhance, accelerate, and/or prolong adaptive immunity against specific vaccine antigens. In this study, we compared the adjuvanticity of two adjuvant formulations containing de- O -acylated lipooligosaccharide (dLOS), a toll-like receptor 4 agonist, on the Japanese encephalitis (JE) vaccine in mice. Mice were immunized once or twice at a two-week interval with inactivated JE vaccine in the absence or presence of adjuvant. We found that both the alum- and the liposome-based formulation induced significantly faster and higher serum IgG antibody responses as compared with the non-adjuvanted vaccine after either one or two immunizations. The antibody titers of the mouse immune sera correlated with 50% plaque reduction neutralization test (PRNT 50 ) antibody titers. In addition, the dLOS/liposome formulation was more effective in inducing a Th1-type immune response than the dLOS/alum formulation, as suggested by a strong antigen-specific interferon (IFN)-γ response. Based on these results, we suggest that both alum- and liposome-based adjuvant formulations containing dLOS may be used for the development of JE vaccines with improved immunogenicity.